Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1] En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]
Lire la suiteThe Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth, Kristen B. Thomas, Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335 Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]
Lire la suitePrevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids. A Systematic Review and Meta-analysis Anees Bahji, MD; Callum Stephenson; Richard Tyo, BSocSc, RP; Emily R. Hawken, MSc, PhD; Dallas P. Seitz, MD, PhD JAMA Network Open, 2020, 3, (4), e202370. doi : 10.1001/jamanetworkopen.2020.2370 Abstract IMPORTANCE : Cannabis withdrawal syndrome (CWS)—a diagnostic indicator of cannabis use disorder—commonly occurs on cessation of heavy and prolonged cannabis use. To date, the prevalence of CWS syndrome has not been well described, nor have the factors potentially associated with CWS. OBJECTIVES : To estimate the prevalence of CWS among individuals with regular or dependent use of [...]
Lire la suiteCannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal Francisco Navarrete, Auxiliadora Aracil-Fernández and Jorge Manzanares British Journal of Pharmacology, 2018. Doi : 10.1111/bph.14226 BACKGROUND AND PURPOSE Cannabidiol (CBD) represents a promising therapeutic tool for treating cannabis use disorder (CUD). This study aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous cannabinoid withdrawal. EXPERIMENTAL APPROACH Spontaneous cannabinoid withdrawal was evaluated 12 h after cessation of CP-55,940 treatment (0.5 mg·kg1 every 12 h, i.p.; 7 days) in C57BL/6J mice. The effects of CBD (5, 10 and 20 mg·kg1, i.p.) on withdrawal-related behavioural signs were evaluated by [...]
Lire la suiteAddiction au cannabis, confinement et détention Jean Michel Delile, David Saint Vincent, Laurent Michel, Patrick Veteau Fédération Addiction, mars 2020 Cannabis et dépendance Longtemps, beaucoup ont pensé que le cannabis n’était pas une drogue (dangereuse), ou alors seulement une drogue « douce », au sens où il n’entrainait pas de syndrome physique de manque, à la différence de l’alcool, des opiacés ou des benzodiazépines… Il a fallu beaucoup de temps aux usagers et aux médecins pour réaliser que l’évidence de la souffrance des patients démontrait que la clef de l’addiction en tant que trouble était plus dans le désir/besoin irrépressible de consommer que dans [...]
Lire la suiteThe therapeutic role of Cannabidiol in mental health : a systematic review Rabia Khan, Sadiq Naveed, Nadeem Mian, Ania Fida, Muhammad Abdur Raafey and Kapil Kiran Aedma Journal of Cannabis Research, 2020, 2, 2 doi : 10.1186/s42238-019-0012-y Abstract Background : The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective : To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders. Materials and method : A systematic review was [...]
Lire la suiteEfficacy of Ketamine in the Treatment of Substance Use Disorders : A Systematic Review Jennifer L. Jones, Camilo F. Mateus, Robert J. Malcolm, Kathleen T. Brad and Sudie E. Back Frontiers in Psychiatry, 2018, 1-10. doi : 10.3389/fpsyt.2018.00277 Abstract Background : Despite advances in behavioral and pharmacotherapy interventions, substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic dysregulation has received increasing attention as one common neuropathology across multiple substances of abuse. Ketamine is a potent N-methyl-D-aspartate (NMDA) glutamatergic receptor antagonist which has been found to be effective in the treatment of severe depression. Here we review the literature on the efficacy of ketamine in [...]
Lire la suiteCannabis use, dependence and withdrawal in indigenous male inmates, Bernadette Rogerson et al., 2014
Cannabis use, dependence and withdrawal in indigenous male inmates Bernadette Rogerson, Susan P. Jacups, and Nerina Caltabiano Journal of Substance Use, 2014, 1–7 DOI: 10.3109/14659891.2014.950702 ISSN: 1465-9891 (print), 1475-9942 (electronic) Abstract Background : No studies have investigated cannabis withdrawal in indigenous or incarcerated populations, and there is currently no standard treatment for cannabis withdrawal in Australian prisons. Aims : This cross sectional survey examines cannabis use, dependence and involuntary (abrupt cessation) withdrawal in incarcerated indigenous males for the purpose of improving clinical management. Methods : 101 consenting inmates (18–40 years) from an Australian correction centre were interviewed. Demographic characteristics, lifetime cannabis use (LCU), severity of dependence, cannabis withdrawal [...]
Lire la suiteCannabis Withdrawal Nicolas J. Schlienz and Ryan Vandrey I. D. Montoya, S. R. B. Weiss (eds.), Cannabis Use Disorders, https://doi.org/10.1007/978-3-319-90365-1_11 Introduction Drug withdrawal refers to a constellation of symptoms that occur following abrupt cessation of chronic drug use. Though drug withdrawal can occur from stopping use of medication, it is most often encountered within the context of illicit, non-medicinal, drug use. The withdrawal symptoms that emerge following extended and frequent use of abused drugs are a key feature of what define substance use disorders [4, 85]. Further, there is accumulating neurobiological evidence that withdrawal drives the maintenance of problematic substance misuse through a mechanism of [...]
Lire la suiteNabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial Jose M. Trigo, Alexandra Soliman, Lena C. Quilty, Benedikt Fischer, JuÈrgen Rehm, Peter Selby, Allan J. Barnes11¤a, Marilyn A. Huestis, Tony P. George, David L. Streiner, Gregory Staios, Bernard Le Foll PLoS ONE, 2018, 13, (1), e0190768. https://doi.org/10.1371/journal.pone.0190768 Abstract Background The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the [...]
Lire la suite